Last updated on February 2020

Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma


Brief description of study

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Detailed Study Description

This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety, tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an anti-CD47 antibody, in subjects with advanced relapsed or refractory solid tumors and lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.

Clinical Study Identifier: NCT03934814

Find a site near you

Start Over

Horizon Oncology

Lafayette, IN United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Gabrail Cancer Center

Canton, OH United States
  Connect »

Mayo Clinic

Scottsdale, AZ United States
  Connect »

Yale School of Medicine

New Haven, CT United States
  Connect »

Mayo Clinic

Jacksonville, FL United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

NYU Langone Health

New York, NY United States
  Connect »